Bifidobacterium longum
AssigneePrecisionBiotics Group Limited
InventorsDavid Groeger, Barry Kiely
Life of this patent
Estimating the term…
Abstract
Bifidobacterium longum strains and cell wall fractions isolated from Bifidobacterium longum strains are useful in the prophylaxis or treatment of an infection in a subject caused by a coronavirus such as SARS-CoV-2. They are also useful in the prophylaxis of a secondary bacterial infection associated with an infection in a subject caused by a coronavirus, especially a subject who is susceptible to respiratory infections.
Claims12
A method for the treatment of a coronavirus infection in a subject, the method comprising administering to the subject in need thereof a formulation comprising at least one Bifidobacterium longum strain or a cell wall fraction isolated from a Bifidobacterium longum strain,
- wherein the coronavirus infection is a SARS-CoV-2 infection,
- wherein a genome of the at least one Bifidobacterium longum strain is not manipulated to produce acquisition or loss of a gene, and
- wherein the at least one Bifidobacterium longum strain is selected from one or more of the strain having the accession number NCIMB 41003, the strain having the accession number NCIMB 41715, the strain having the accession number NCIMB 41713, or the strain having the accession number NCIMB 42020.
Dependencies are inferred from the claim text.